Nerve Agent Articles & Analysis
8 news found
Under this contract (number 75A50122C00082), awarded under the 2004 Project BioShield Act, Aktiv will supply emergency autoinjectors containing pralidoxime chloride (2-PAM) to the CHEMPACK program, targeting proposed indications related to organophosphate poisoning including nerve agents. The total value of the contract, including options to continue supplying ...
OnLume Inc., a Madison, Wisconsin-based medical imaging company with unique technology for improving surgical precision in the operating room, has announced the start of participation in a clinical trial combining its fluorescence-guided surgery (FGS) imaging device with a novel nerve-targeting agent. OnLume has unique FGS imaging technology to illuminate ...
Aktiv is leveraging its superior autoinjector technology to advance the strongest emergency treatment pipeline in the industry, which currently includes atropine, pralidoxime chloride (2-PAM), atropine/2-PAM dual-injection, and scopolamine in development as a treatment for nerve agent poisoning, and is planning to add at least one more emergency treatment to its ...
This allows ALM-488 to highlight multiple types of nerves including motor, sensory, autonomic and degenerated nerves important during reconstructive procedures. Surgeries where nerves are potentially at risk include procedures in the skull base, head and neck, spine, and nerve sparing prostatectomy. ...
Alume previously received a Phase I SBIR grant in 2019 from the NINDS to develop nerve illumination agents for surgical use. The Phase II SBIR grant is a follow-on 2–year award that will support testing of Alume's fluorescent nerve targeting agent in an ongoing Phase 1/2 clinical trial in patients undergoing Head and Neck ...
Subsequently, in 2018, BARDA awarded Aktiv Pharma Group a $15.5 million contract to develop a Good Manufacturing Practice (GMP) manufacturing line for the ARAI autoinjector platform, which was completed in December 2019. 2-PAM is an antidote to poisoning by organophosphate nerve agents such as sarin, soman, and VX. These nerve ...
[BROOMFIELD, MARCH 23, 2020] Aktiv Pharma Group has been awarded a $24.5 million US government project to develop an autoinjector treatment for exposure to nerve agents. The award is an Other Transaction (OT) prototype project by the Department of Defense (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEOCBRND). ...
We share a common interest by helping protecting the forces’ troops against nerve agents’ attacks. The Food and Drug Administration and the DOD are really working together to help with development and use of specific pharmaceutical products. ...